“It is just that we have a strong domestic investor sentiment and about $2 billion per month is the incremental SIP which I think to an extent is ensuring that markets are not really crashing,” says Sudip Bandyopadhyay, Inditrade Capital. Just wanted to understand from you that from the earnings, which sector that you are … Read more
Brokerage firms such as Investec maintained a buy rating on Jindal Stainless. Bernstein recommends an outperform on Cipla, JPMorgan has a neutral rating on Maruti Suzuki and Motilal Oswal recommends a buy on Max Healthcare. We have collated a list of recommendations from top brokerage firms from ETNow and other sources: Investec on Jindal Stainless: … Read more
ET Intelligence Group: If the diktat of the National Medical Commission (NMC) mandating doctors to prescribe only generic drugs indeed gets implemented, drug marketing in India is likely to witness five major changes.1. Companies with not-so-strong brands are likely to face the heat.Mid-sized pharma companies having brands that are not in top-ten in their therapies … Read more
Indian market bounced back after falling for 3 consecutive days on Friday. The S&P BSE Sensex rose nearly 500 points while the Nifty50 managed to close above 19500 levels. Sectorally, buying was seen in IT, telecom, energy and realty stocks while some selling was seen in public sector, auto, power and utilities. Stocks that were … Read more
Vinit Bolinjkar, Head-Equity Research, Ventura Securities, says RBL is definitely a stock to buy. So, irrespective of Mahindra putting money into this stock, we had a buy on this stock at Rs 130 with a target of Rs 260. Today, we are sitting around 210-220 odd levels still a way to go and our estimates … Read more
Benchmark indices resumed their losing streak after the US Fed left room for more interest rate hikes in the future. The Sensex fell 440 points to settle at 66,266, while the broader Nifty declined 118 points to end at 19,659. Stocks that were in focus include names like Cipla, which rose 9.78%, RVNL, which fell … Read more
Mumbai: Shares of drugmaker Cipla surged nearly 10% on Thursday as analysts raised their price targets on the stock after better-than-expected first quarter results. These analysts have increased their price targets by 2-35%, according to data compiled by Bloomberg. The average price target of the 28 analysts, whose ratings and price targets that have been … Read more
Rahul Sharma, Director, JM Financial Services, says “there is a very big breakout in Grasim. About 21 months of consolidation. Finally,, cement stocks are seeing a bit of attraction this week. Rs 2,200-2,500 is the projected target for the next 12 months. So both short term and long term, Grasim looks pretty solid. Also, go … Read more
Kotak Institutional Equities initiated coverage on Mankind Pharma stock with ‘Add’ rating for a price target of Rs 1,875. The domestic brokerage sees an 11% upside in the counter from current levels. “Mankind Pharma is well-positioned to further leverage its robust marketing prowess and reach. Within branded Rx, we expect a ramp-up of specialty and … Read more
“Question is whether you will get an allotment or not because of the heavy over subscription. But, from retail investor perspective, it is a good opportunity and perhaps you could even add some stock post listing,” says Dipan Mehta, Director, Elixir Equities.Mankind Pharma, an offering from the pharma sector after a while, wanted to understand … Read more